Advances In Managing Paralytic Strabismus: A Look Toward The Future


This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. 


In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged by disease, injured by trauma, or worn by time to normal function. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.


Paralytic strabismus is a condition that affects the eye muscles, causing them to be unable to move correctly. This can lead to double vision, an inability to move the eye, and a droopy eyelid. Up to 1.93% of the population is estimated to suffer from some form of strabismus. This prevalence highlights the importance of understanding and managing this condition.


The good news is that various treatments are available, including eye exercises, corrective lenses, prism glasses, eye surgery, and the promising botulinum toxin injection. By understanding the different causes and treatments, individuals with paralytic strabismus can receive the best possible care and support.


Understanding Paralytic Strabismus


Paralytic strabismus is a condition that affects the eye muscles, resulting in an inability to move them correctly. This condition is also known as paralytic squint and is often characterized by double vision or diplopia. Paralytic strabismus can be caused by the involvement of the third, fourth, or sixth cranial nerves and can be either congenital or acquired.


The symptoms of paralytic strabismus can vary depending on the extent of the muscle paralysis. Common symptoms of this condition include droopy eyelids, a misaligned eye, and an inability to move the eye correctly. The severity of the symptoms can range from mild to severe and can impact an individual’s visual function significantly.


What Causes Paralytic Strabismus?


This condition can occur due to several factors, which may vary depending on the age of onset and the muscles involved.


In children, paralytic strabismus is often caused by congenital malformations that affect the muscles responsible for eye movement. This can include conditions such as Duane syndrome, which affects the eye’s ability to move inward or outward, or congenital fibrosis syndrome, which affects the eye’s ability to move in any direction.


In adults, paralytic strabismus is usually the result of trauma, infections, or neurological disorders. Trauma to the eye or head can cause damage to the muscles responsible for eye movement, resulting in paralytic strabismus. Infections such as botulism, Lyme disease, or herpes simplex virus can also cause this condition.


Neurological disorders such as multiple sclerosis, stroke, or brain aneurysms can also lead to paralytic strabismus. These conditions affect the brain’s ability to control eye movement, leading to misalignment or abnormal eye movements.


Current Treatments


The treatment for this condition is based on the individual’s needs and the severity of the problem. Treatment options for paralytic strabismus include eye exercises, corrective lenses, prism glasses, and eye surgery. Eye exercises are often recommended to strengthen the muscles responsible for eye movement, which can improve the alignment of the eyes. 


Corrective lenses may also be prescribed to help correct refractive errors, which can contribute to the development of strabismus. Prism glasses may be recommended to help align the eyes by bending light rays, which can help reduce the severity of the condition. Eye surgery is also an option for those with severe cases of paralytic strabismus, where the muscles responsible for eye movement are adjusted to improve alignment.


BOTOX for Strabismus


Botulinum toxin injection is a promising treatment for the management of paralytic strabismus. This innovative, non-invasive treatment involves injecting botulinum toxin into the affected muscles, which works by blocking the release of acetylcholine – the neurotransmitter responsible for the excitation of muscle fibers. As a result, the muscles in question become weakened, leading to relief from muscle spasms and other symptoms of paralytic strabismus.


The benefits of this treatment are numerous, including reduced recovery time and the avoidance of risks commonly associated with anesthesia. Moreover, the procedure can be done on an outpatient basis, allowing patients to return home the same day.


Clinical trials show that botulinum toxin injection is most effective in managing certain types of paralytic strabismus. This treatment has been found to work well for conditions such as esotropia or exotropia with a small-to-moderate angle deviation, acute onset comitant esotropia, and acute paralytic strabismus that can cause double vision.


Regarding long-term success rates, a retrospective chart review of 51 patients with paralytic strabismus who received botulinum A toxin (BTXA) chemodenervation reported an average decrease of 25.2 prism diopters in the angle of deviation. This suggests that BTXA chemodenervation could be ideal as the first-line treatment option for patients with paralytic strabismus.


Toward the Future


Looking toward the future, there is a positive outlook for managing paralytic strabismus. With the development of new technologies and treatments, the management of this condition will likely continue to advance, leading to improved outcomes and better long-term prognosis for individuals living with paralytic strabismus. By continuing to research and invest in the development of innovative treatments, we can ensure that individuals with paralytic strabismus have access to the best possible care and support.

To learn more about the eye, read more stories at

© William A. Haseltine, PhD. All Rights Reserved.